Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials near Los Angeles, CA

178 studies for Breast Cancer are recruiting at 499 sites within 50 miles of Los Angeles, California, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near Los Angeles.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Breast Cancer studies enrolling near Los Angeles

Showing the 50 nearest of 178 studies.
  1. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Cedars Sinai Medical Center (Los Angeles, CA); Kaiser Permanente Los Angeles Medical Center (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    26 sites within 50 mi
  2. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female

    Nearest sites: Cedars-Sinai Medical Center (Los Angeles, CA); Kaiser Permanente Los Angeles Medical Center (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    25 sites within 50 mi
  3. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    NCT06072612

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Cedars-Sinai Cancer at Cedars-Sinai Medical Facility (Los Angeles, CA); Los Angeles Cancer Network (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    21 sites within 50 mi
  4. E-Mindfulness Approaches for Living After Breast Cancer

    NCT06748222

    • Phase 3
    • Ages 18 to 50 years
    • Sex: All

    Nearest sites: Kaiser Permanente Los Angeles Medical Center (Los Angeles, CA); Kaiser Permanente West Los Angeles (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    19 sites within 50 mi
  5. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    NCT06058377

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Cedars-Sinai Medical Center (Los Angeles, CA); The Angeles Clinic and Research Institute - West Los Angeles Office (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    18 sites within 50 mi
  6. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All

    Nearest sites: Cedars Sinai Medical Center (Los Angeles, CA); Kaiser Permanente Los Angeles Medical Center (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    14 sites within 50 mi
  7. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    NCT03723928

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Kaiser Permanente Los Angeles Medical Center (Los Angeles, CA); Kaiser Permanente West Los Angeles (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    12 sites within 50 mi
  8. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: UCLA Department of Medicine - Hematology/Oncology (Los Angeles, CA); USC/Norris Comprehensive Cancer Center (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    10 sites within 50 mi
  9. A Study of Sigvotatug Vedotin in Advanced Solid Tumors

    NCT04389632

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Ronald Reagan UCLA Medical Center (Los Angeles, CA); The Regents of the University of California (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 50 mi
  10. Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

    NCT05595499

    • Phase 2
    • Ages Any age
    • Sex: Female

    Nearest sites: UCLA / Jonsson Comprehensive Cancer Center (Los Angeles, CA); UCLA Health Cancer Care in Alhambra (Alhambra, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 50 mi
  11. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Cedars-Sinai Medical Center (Los Angeles, CA); Huntington Memorial Hospital (Pasadena, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 50 mi
  12. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    NCT03418961

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: USC / Norris Comprehensive Cancer Center (Los Angeles, CA); City of Hope South Pasadena (South Pasadena, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  13. Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors

    NCT06113016

    • Phase 2
    • Ages Any age
    • Sex: Female

    Nearest sites: UCLA / Jonsson Comprehensive Cancer Center (Los Angeles, CA); UCLA Health Cancer Care in Alhambra (Alhambra, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  14. Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

    NCT04553770

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: UCLA / Jonsson Comprehensive Cancer Center (Los Angeles, CA); PIH Health (Whittier, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  15. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377

    • Phase 2
    • Ages Any age
    • Sex: All

    Nearest sites: Cedars-Sinai Medical Center (Los Angeles, CA); The Angeles Clinic and Research Institute - West Los Angeles Office (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  16. Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

    NCT05827081

    • Phase 3
    • Ages 18 to 100 years
    • Sex: All

    Nearest sites: Los Angeles Cancer Network Good Samaritan (Los Angeles, CA); City of Hope National Medical (Duarte, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  17. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

    NCT05894239

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Ellison Medical Institute (Los Angeles, CA); Disney Family Cancer Center (Burbank, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  18. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    NCT06324357

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Ellison Medical Institute (Los Angeles, CA); University of California Los Angeles (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  19. A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

    NCT06369285

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: LA Cancer Network (Los Angeles, CA); UCLA Department of Medicine - Hematology/Oncology (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  20. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    NCT06790693

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Ellison Medical Institute (Los Angeles, CA); Disney Family Cancer Center (Burbank, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  21. Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

    NCT05372640

    • Phase 1
    • Ages 12 years and older
    • Sex: All

    Nearest sites: Keck Medicine of USC Koreatown (Los Angeles, CA); Los Angeles General Medical Center (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  22. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    NCT05877599

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Research Site (Los Angeles, CA); Research Site (Santa Monica, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  23. A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis

    NCT06336928

    • Observational
    • Ages 18 years and older
    • Sex: Female

    Nearest sites: Keck Medicine of USC Koreatown (Los Angeles, CA); Los Angeles General Medical Center (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  24. Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

    NCT06380751

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Research Site (Los Angeles, CA); Research Site (Glendale, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  25. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

    NCT06926868

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: USC/Norris Comprehensive Cancer Center (Los Angeles, CA); Valkyrie Clinical Trials (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  26. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    NCT01042379

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Southern California (Los Angeles, CA); City of Hope (Duarte, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  27. A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

    NCT03424005

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: UCLA Health 200 Medical Plaza (Los Angeles, CA); City of Hope - Duarte (Duarte, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  28. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    NCT05005403

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: USC Norris Comprehensive Cancer Center /ID# 279603 (Los Angeles, CA); City of Hope National Medical Center /ID# 276272 (Duarte, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  29. Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

    NCT05297734

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Oncology Institute for Hope and Innovation (Los Angeles, CA); Beckman Research Institute of City of Hope (Duarte, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  30. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    NCT05633654

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Cedars-Sinai Cancer at Beverly Hills (Los Angeles, CA); PIH Health Whittier Hospital (Downey, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  31. IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases

    NCT06092892

    • Phase 2
    • Ages 45 years and older
    • Sex: Female

    Nearest sites: Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (Los Angeles, CA); CS Cancer at Huntington Cancer Center (Pasadena, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  32. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    NCT06293898

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Cedars Sinai (Los Angeles, CA); START - Los Angeles (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  33. A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

    NCT06435429

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS (Los Angeles, CA); Los Angeles Hematology Oncology Medical Group Glendale (Glendale, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  34. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    NCT06582017

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Cedars-Sanai Medical Center (Los Angeles, CA); Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  35. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    NCT06841354

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: UCLA Department of Medicine - Hematology & Oncology ( Site 0047) (Los Angeles, CA); City of Hope ( Site 0097) (Duarte, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  36. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    NCT06982521

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Cedars-Sinai Medical Center (Los Angeles, CA); Beverly Hills Cancer Center (Beverly Hills, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  37. Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

    NCT07017673

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Cedars-Sinai Medical Center (Los Angeles, CA); Cedars-Sinai Medical Center Beverly Hills (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  38. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

    NCT07173751

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Cedar Sinai - Samuel Oschin Cancer Center (Los Angeles, CA); Saint John's Health Center - John Wayne Cancer Institute (JWCI) (Santa Monica, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  39. Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

    NCT02620852

    • Interventional
    • Ages 30 to 74 years
    • Sex: Female
    • Accepts healthy volunteers

    Nearest sites: University of California Los Angeles (Los Angeles, CA); University of California Irvine (Irvine, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  40. Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

    NCT04119024

    • Phase 1
    • Ages 18 to 75 years
    • Sex: All

    Nearest sites: UCLA / Jonsson Comprehensive Cancer Center (Los Angeles, CA); City of Hope (Duarte, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  41. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    NCT04585750

    • Phase 1/2
    • Ages 12 years and older
    • Sex: All

    Nearest sites: UCLA Jonsson Comprehensive Cancer Center (Los Angeles, CA); USC Norris Comprehensive Cancer Center (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  42. Study of PF-07248144 in Advanced or Metastatic Solid Tumors

    NCT04606446

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Cedars Sinai Medical Center (Los Angeles, CA); Cedars-Sinai Cancer at Cedars-Sinai Medical Center (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  43. A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

    NCT04895709

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: USC/Norris Comprehensive Cancer Center (Los Angeles, CA); Hoag Memorial Hospital Presbyterian (Newport Beach, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  44. Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

    NCT05386108

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: California Research Institute (Los Angeles, CA); Providence Medical Foundation (Fullerton, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  45. A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

    NCT05902988

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Southern California (Los Angeles, CA); Hoag Memorial Hospital (Newport Beach, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  46. Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses

    NCT06171607

    • Phase 1
    • Ages 18 years and older
    • Sex: Female

    Nearest sites: Los Angeles County-USC Medical Center (Los Angeles, CA); USC / Norris Comprehensive Cancer Center (Los Angeles, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  47. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    NCT06465069

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: UCLA Department of Medicine-Hematology/Oncology (Los Angeles, CA); City of Hope National Medical Center (Duarte, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  48. Study of XB010 in Subjects With Solid Tumors

    NCT06545331

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: UCLA Department of Medicine - Hematology/Oncology (Los Angeles, CA); City of Hope Orange County Lennar Foundation Cancer Center (Irvine, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  49. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    NCT06625775

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of California Los Angeles (Los Angeles, CA); City of Hope Comprehensive Cancer Center (Duarte, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  50. Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    NCT06757634

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: UCLA Hematology Oncology Santa Monica (Los Angeles, CA); Providence Medical Foundation (Fullerton, CA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.